ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy

Draig Therapeutics Raises $140M Series A to Advance Neuropsychiatric Drug Pipeline

Draig Therapeutics; $140M Series A; neuropsychiatric drugs; DT-101; depression treatment; AMPA receptor modulator; GABA modulators; biotech funding; Cardiff University; SV Health Investors

FDA Launches New Priority Review Voucher Program Aligned with National Priorities

FDA; priority review voucher; CNPV; biopharma; drug approval; national priorities; accelerated review; unmet public health needs